Daclizumab

Bibliography

• GOEBEL J, STEVENS E, FORREST K et al.: Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol. (2000) (8):153-159.
   PubMed Web of Science ®Google Scholar
• KIRKMAN RL, SHAPIRO ME, CARPENTER CB et al.: A randomised prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation (1991) 51(1):107-113.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, PACE D, BIRNBAUM J, LANTZ M: Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am. J. Transplant. (2003) 3(1):50-52.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, KIRKMAN R, LIGHT S et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl. J. Med. (1998) 338(3):161-165.
   PubMed Web of Science ®Google Scholar
• NIEMEYER G, KOCH M, LIGHT S, KUSE ER, NASHAN B: Long term safety, tolerability and efficacy of daclizumab (Zenepax) in a two-dose regimen in liver transplant recipients. Am. J. Transplant. (2002) 2(5):454-460.
   PubMed Web of Science ®Google Scholar
• SELLERS MT, MCGUIRE BM, HAUSTEIN SV, BYNON JS, HUNT SL, ECKHOFF DE: Two- dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation (2004) 78(8):1212-1217.
   PubMed Web of Science ®Google Scholar
• EKBERG H, PERSSON NH, KALLEN R, GUL-BAYKURT N: Two doses of daclizumab in conjuction with low-dose cyclosporin, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand. J. Immunol. (2003) 58(6):670-677.
   PubMed Web of Science ®Google Scholar
• OSUNA A, GENTIL MA, CAPDEVILA L et al.; Spanish Kidney Transplant of Elderly Donor Study Group: Two doses of daczilumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadeveric renal transplants from donors > 55 years of age. Transplant. Proc. (2005) 37(3):1438-1440.
   PubMed Web of Science ®Google Scholar
• JOYAL D, CANTAROVICH M, CECERE R, GIANNETTI N: Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation. Clin. Transplant. (2004) 18(5):493-496.
   PubMed Web of Science ®Google Scholar
• KOCH M, NIEMEYER G, PATEL I, LIGHT S, NASHAN B: Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation (2002) 73(10):1640-1646.
   PubMed Web of Science ®Google Scholar
• MEDICAL ECONOMICS STAFF: Physician's Desk Reference. Medical Economics Company, Montvale, NJ, USA (1998).
   Google Scholar
• BAUDOUIN V, CRUSIAUX A, HADDAD E et al.: Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation (2003) 76(3):459-463.
   PubMed Web of Science ®Google Scholar
• BROCK MV, BORJA MC, FERBER L et al.: Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant. (2001) 20(12):1282-1290.
   PubMed Web of Science ®Google Scholar
• BHORADE SM, VILLANUEVA J, JORDAN AM et al.: New combination of immunosuppressive therapy decreases acute rejection in lung transplantation. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9 – 12 April 2003):(Abstract 143).
   Google Scholar
• CONTE JV, ALLAN SH, BORJA MC et al.: Is acute rejection primary in the development of obliterative bronchiolitis? A retrospective study of daclizumab and thymoglobulin. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9 – 12 April 2003):(Abstract 150).
   Google Scholar
• LISCHKE R, SIMONEK J, DAVIDOVA R et al.: Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant. Proc. (2007) 39(1):205-212.
   PubMed Web of Science ®Google Scholar
• MULLEN JC, OREOPOULOS A, LIEN DC et al.: A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J. Heart Lung Transplant. (2007) 26(5):504-510.
   PubMed Web of Science ®Google Scholar
• BURTON CM, ANDERSEN CB, JENSEN AS et al.: The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J. Heart Lung Transplant. (2006) 25(6):638-647.
   PubMed Web of Science ®Google Scholar
• HERSHBERGER RE, STARLING RC, EISEN HJ et al.: Daclizumab to prevent rejection after cardiac transplantation. N. Engl. J. Med. (2005) 352(26):2705-2713.
   PubMed Web of Science ®Google Scholar
• BENIAMINOVITZ A, ITESCU S, LIETZ K et al.: Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. (2000) 342(9):613-619.
   PubMed Web of Science ®Google Scholar
• KOBASHIGAWA J, DAVID K, MORRIS J et al.: Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine and corticosteroids. Transplant. Proc. (2005) 37(2):1333-1339.
   PubMed Web of Science ®Google Scholar
• ORTIZ V, ALMENAR L, MARTINEZ-DOLZ L et al.: Induction therapy with daclizumab in heart transplantation – how many doses? Transplant. Proc. (2006) 38(8):2541-2543.
   PubMed Web of Science ®Google Scholar
• CUPPOLETTI A, PEREZ-VILLA F, VALLEJOS I, ROIG E: Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Transplant. Proc. (2005) 37(9):4036-4038.
   PubMed Web of Science ®Google Scholar
• NASHAN B, LIGHT S, HARDIE I, LIN A, JOHNSON J: Reduction of acute renal allograft rejection by daclizumab: daclizumab double therapy study group. Transplantation (1999) 67(1):110-115.
   PubMed Web of Science ®Google Scholar
• BUMGARDNER GL, RAMOS E, LIN A, VINCENTI F: Daclizumab triple therapy and double therapy groups. Daclizumab (Humanized Anti-IL2Rα mAB) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation (2001) 72(4):642-647.
   PubMed Web of Science ®Google Scholar
• ADU D, COCKWELL P, IVES NJ, SHAW J, WHEATLEY K: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ (2003) 326:789-794.
   PubMed Web of Science ®Google Scholar
• MORRIS JA, HANSON JE, STEFFEN BJ et al.: Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin. Transplant. (2005) 19(3):340-345.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, SUZART K et al.: Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. Transplant. Proc. (2003) 35(2):873-874.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, GAYNOR JJ et al.: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation (2004) 77(2):244-251.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, GAYNOR JJ et al.: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation (2004) 77(2):252-258.
   PubMed Web of Science ®Google Scholar
• KUYPERS DR, EVENEPOEL P, MAES B, COOSEMANS W, PIRENNE J, VANRENTERGHEM Y: The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin. Transplant. (2003) 17:234-241.
   PubMed Web of Science ®Google Scholar
• PESCOVITZ MD, BUMGARDNER G, GASTON RS et al.: Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin. Transplant. (2003) 17(6):511-517.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, RAMOS E, BRATTSTROM C et al.: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 71(9):1282-1287.
   PubMed Web of Science ®Google Scholar
• AHSAN N, HOLMAN MJ, JAROWENKO MV, RAZZAQUE MS, YANG HC: Limited dose monoclonal IL-2 antibody induction protocol after primary kidney transplantation. Am. J. Transplant. (2002) 2(6):568-573.
   PubMed Web of Science ®Google Scholar
• PHILOSOPHE B, WILAND AM, MANN DL et al.: Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function. Scientific Program: American Transplant Congress. Washington, DC, USA (26 April – 1 May 2002):(Abstract 402).
   Google Scholar
• KANDUS A, GREGO K, BREN AF: Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients. Ther. Apher. Dial. (2005) 9(3):262-264.
   PubMed Web of Science ®Google Scholar
• REHMAN LU, ATKINSON RC: Two dose daclizumab (Zenapax) is safe and effective induction therapy in adult renal transplantation (Abstract). Am. J. Transplant. (2001) 1(Suppl. 1):300 (Abstract 655).
   Google Scholar
• DEIERHOI MH, HUDSON SL, GASTON RS: Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation (Abstract). Transplantation (2000) 69:S260 (Abstract 574).
   Google Scholar
• EKBERG H, GRINYO J, NASHAN B et al.; ON BEHALF OF THE CAESAR STUDY GROUP: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am. J. Transplant. (2007) 7(3):560-570.
   PubMed Web of Science ®Google Scholar
• SHEASHAA HA, BAKR MA, FOUDA MA et al.: Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up. Int. Urol. Nephrol. (2007) 39(1):317-319.
   PubMed Web of Science ®Google Scholar
• SANDRINI S: Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin. Transplant. (2005) 19(6):705-710.
   PubMed Web of Science ®Google Scholar
• HARIHARAN S, JOHNSON C, BRESNAHAN BA, TARANTO SE, MCINTOSH MJ, STABLEIN D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. (2000) (342):605-612
   PubMed Web of Science ®Google Scholar
• SANDRINI S: Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin. Transplant. (2005) 19(6):705-710.
   PubMed Web of Science ®Google Scholar
• STRATTA RJ, ALLOWAY RR, LO A, HODGE EE: A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney–pancreas transplantation: results at 3 years. Transplant. Proc. (2005) 37(8):3531-3534.
   PubMed Web of Science ®Google Scholar
• HUURMAN VA, KALPOE JS, VAN DE LINDE P et al.: Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care (2006) 29(4):842-847.
   PubMed Web of Science ®Google Scholar
• BECKER LE, NOGUEIRA VA, ABENSUR H et al.: No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: a comparative analysis. Transplant. Proc. (2006) 38(6):1933-1936.
   PubMed Web of Science ®Google Scholar
• ORR DW, PORTMANN BC, KNISELY AS et al.: Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant. Proc. (2005) 37(10):4373-4379.
   PubMed Web of Science ®Google Scholar
• WASHBURN WK, TEPERMAN LW, HEFFRON TG et al.: A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. Liver Transplant. (2006) 12(4):585-591.
   PubMed Web of Science ®Google Scholar
• FIGUERAS J, PRIETO M, BERNARDOS A et al.: Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transplant. Int. (2006) 19(8):641-648.
   PubMed Web of Science ®Google Scholar
• ECKHOFF DE, MCGUIRE B, SELLERS M et al.: The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation (2000) 69(9):1867-1872.
   PubMed Web of Science ®Google Scholar
• FIGUERAS J, BERNARDOS A, PRIETO M et al.: Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant. Proc. (2002) 34(5):1511-1513.
   PubMed Web of Science ®Google Scholar
• WASHBURN K, SPEEG KV, ESTERL R et al.: Steroid elimination 24 h after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation (2001) 72(10):1675-1679.
   PubMed Web of Science ®Google Scholar
• HEFFRON TG, SMALLWOOD GA, PILLEN T et al.: Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant. Proc. (2002) 34(5):1514-1515.
   PubMed Web of Science ®Google Scholar
• HEFFRON TG, PILLEN T, SMALLWOOD GA et al.: Pediatric liver transplantation with daclizumab induction therapy. Transplantation (2003) 75(12):2040-2043.
   PubMed Web of Science ®Google Scholar
• YOSHIDA EM, MAROTTA PJ, GREIG PD et al.: Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transplant. (2005) 11(9):1064-1072.
   PubMed Web of Science ®Google Scholar
• LIN M, MING A, ZHAO M: Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin. Transplant. (2006) 20(3):325-329.
   PubMed Web of Science ®Google Scholar
• PHAM K, KRAFT K, THIELKE J et al.: Limited-dose daclizumab versus basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant. Proc. (2005) 37(2):899-902.
   PubMed Web of Science ®Google Scholar
• WEBSTER AC, PLAYFORD EG, HIGGINS G, CHAPMAN JR, CRAIG JC: Interleukin-2 receptor antagonists for renal transplant recipients: a meta-analysis of randomised trials. Transplantation (2004) 77(2):166-176.
   PubMed Web of Science ®Google Scholar
• VAN GELDER T, WARLE M, TER MEULEN RG: Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs (2004) 64(16):1737-1741.
   PubMed Web of Science ®Google Scholar
• CAMPOS A, LAGE E, HINOJOSA R et al.: Comparative study of muromab-CD3 (OKT3) versus daclizumab (Zenepax) in cardiac transplantation at our center. Transplant. Proc. (2005) 37(3):1548-1549.
   PubMed Web of Science ®Google Scholar
• CARLSEN J, JOHANSEN M, BOESGAARD S et al.: Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J. Heart Lung Transplant. (2005) 24(3):296-302.
   PubMed Web of Science ®Google Scholar
• ABOU-JAOUDE MM, GHANTOUS I, ALMAWI WY: Comparison of daclizumab, an interleukin-2-receptor antibody to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol. Immunol. (2003) 39(17-18):1083-1088.
   PubMed Web of Science ®Google Scholar
• CHERIKH WS, KAUFFMAN HM, MCBRIDE MA, MAGHIRANG J, SWINNEN LJ, HANTO DW: Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation (2003) 76(9):1289-1293.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, SANDBORN WJ, FEAGAN BG et al.: Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut (2006) 55(11):1568-1574.
   PubMed Web of Science ®Google Scholar
• TEACHEY DT, BICKERT B, BUNIN N: Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant. (2006) 37(1):95-99.
   PubMed Web of Science ®Google Scholar
• TER MEULEN CG, JACOBS CW, WETZELS JF, KLASEN IS, HILBRANDS LB, HOITSMA AJ: The fractional excretion of soluble interleukin-2 receptor-α is an excellent predictor of the interleukin-2 receptor-α status after treatment with daclizumab. Transplantation (2004) 77(2):281-286.
   PubMed Web of Science ®Google Scholar
• PRZEPIORKA D, KERNAN NA, IPPOLITI C et al.: Daclizumab, a humanised anti-interleukin-2 receptor α chain antibody, for treatment of acute graft-versus-host disease. Blood (2000) 95(1):83-89.
   PubMed Web of Science ®Google Scholar
• LEE SJ, ZAHRIEH D, AGURA E et al.: Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomised trial. Blood (2004) 104(5):1559-1564.
   PubMed Web of Science ®Google Scholar
• BORDIGONI P, DIMICOLI S, CLEMENT L et al.: Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br. J. Haematol. (2006) 135(3):382-385.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, PETERSON JS, FOSTER CS et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology (2005) 112(5):764-770.
   PubMed Web of Science ®Google Scholar
• SZABOLCS P, REESE M, YANCEY KB, HALL RP, KURTZBERG J: Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. (2002) 30(5):327-329.
   PubMed Web of Science ®Google Scholar
• MACIEJEWSKI JP, SLOAND EM, NUNEZ O, BOSS C, YOUNG NS: Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood (2003) 102(10):3584-3586.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, RICHERT N, HOWARD T et al.: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc. Natl. Acad. Sci. USA (2004) 101(23):8705-8708.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, CATALFAMO M, REICHERT-SCRIVNER S et al.: Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2R α-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA (2006) 103(15):5941-5946.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: The interleukin-2 receptor. J. Biol. Chem. (1991) (266):2681-2684.
   PubMed Web of Science ®Google Scholar
• LINDEN O: Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. N. Engl. J. Med. (2004) 351(14):1466-1467.
   PubMed Web of Science ®Google Scholar
• OSBORNE GE, PAGLIUCA A, HO A, DU VIVIER AW: Novel treatment of sezary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor α antibody). Br. J. Dermatol. (2006) 155(3):617-620.
   PubMed Web of Science ®Google Scholar
• KOON HB, SEVERY P, HAGG DS et al.: Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk. Res. (2006) 30(2):190-203.
   PubMed Web of Science ®Google Scholar
• CIANCIO G, BURKE GW, SUZART K et al.: Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant. Proc. (2002) 34(5):1944-1945.
   PubMed Web of Science ®Google Scholar
• SARWAL MM, VIDHUN JR, ALEXANDER SR, SATTERWHITE T, MILLAN M, SALVATIERRA O Jr: Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation (2003) 76(9):1331-1339.
   PubMed Web of Science ®Google Scholar